TOKYO--(BUSINESS WIRE)--Malignant Tumor Treatment Technologies, Inc. (Headquarters: Tokyo; President and CEO: Toshiyasu Miyazaki; “M.T.3”) announced today that the Japanese pharmaceutical regulatory agency, the Ministry of Agriculture, Forestry, and Fisheries, has granted approval for LAVURCHIN® as a radiation sensitizing agent for dogs with stage III or stage IV nasal cavity tumors..

东京-（商业线）-恶性肿瘤治疗技术有限公司（总部：东京；总裁兼首席执行官：宫崎敏三；“M.T.3”）今天宣布，日本农业部林业和渔业部已批准LAVURCHIN®作为III期或IV期鼻腔肿瘤犬的放射增敏剂。。

Radiation therapy, a crucial treatment for malignant tumors that cannot be completely removed through surgery, has seen significant advancements in recent years in both human and veterinary medicine. However, challenges such as limitations on the number of radiation sessions and decreased effectiveness as tumors progress have highlighted the need for a radiation sensitizing agent to enhance treatment outcomes.

放射治疗是一种无法通过手术完全切除的恶性肿瘤的重要治疗方法，近年来在人类和兽医学方面取得了重大进展。然而，随着肿瘤进展，辐射疗程数量的限制和有效性的降低等挑战突出了放射增敏剂增强治疗效果的必要性。

Despite several candidate substances being studied, none have obtained pharmaceutical approval due to concerns about side effects..

尽管正在研究几种候选物质，但由于担心副作用，没有人获得药物批准。。

After a long and challenging endeavor lasting over two and a half decades, 'LAVURCHIN®' has emerged as a groundbreaking solution as the world’s first radiation sensitizing agent in the veterinary field approved by the Japanese Ministry of Agriculture, Forestry, and Fisheries (MAFF), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA).

经过长达二十五年的长期挑战性努力，“LAVURCHIN®”已成为世界上第一个由日本农林渔业部（MAFF）批准的兽医领域辐射增敏剂的开创性解决方案，美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）。

Derived from marine organisms, including sea urchins from Hokkaido, a northern region of Japan, and deep-sea seaweed, this innovative agent not only enhances the effects of radiation therapy but also minimizes damage to normal tissues, ensuring high safety standards..

这种创新剂来源于海洋生物，包括来自日本北部地区北海道的海胆和深海海藻，不仅可以增强放射治疗的效果，还可以最大限度地减少对正常组织的损害，确保高安全标准。。

'We are delighted to announce the approval of LAVURCHIN® as the world's first radiation sensitizing agent for dogs,' said Toshiyasu Miyazaki, President and CEO of M.T.3. 'This significant milestone is a testament to our commitment to advancing cancer treatment and improving the lives of both animals and humans.

“我们很高兴宣布批准LAVURCHIN®作为世界上第一个狗的辐射增敏剂，”M.T.3总裁兼首席执行官宫崎敏彦说这个重要的里程碑证明了我们致力于推进癌症治疗和改善动物和人类的生活。

We will continue our endeavors to make LAVURCHIN® available to those in need around the world.'.

我们将继续努力使LAVURCHIN®可供世界各地有需要的人使用。

In parallel with the Japanese approval, M.T.3 is conducting clinical research on 'LAVURCHIN®' in the United States, demonstrating a global perspective. The company envisions bringing this revolutionary product to markets worldwide, including the United States, Europe, and Asia. Furthermore, future expansion into human medicine is also being considered..

在日本批准的同时，M.T.3正在美国对'LAVURCHIN®'进行临床研究，展示了全球视角。该公司设想将这一革命性产品推向全球市场，包括美国，欧洲和亚洲。此外，还正在考虑未来扩展到人类医学。。